Before NSF bought Amarex they would have done their due diligence. They would have wanted to see the July 2019 response letter from the FDA showing the discrepancies in the BLA filing. They would have certainly had access to the January 2020 FDA letter. That NSF would have so little regard of one of their assets that they were not providing guidance is unrealistic. The records and email trail between NSF and Amarex will prove that. I wouldn't be surprised if NSF sent troubleshooters in to try and fix the BLA after January 2020.